摘要
目的探讨冠心病心力衰竭患者联合给予美托洛尔与曲美他嗪的影响。方法选取2019年4月—2020年4月期间在该院进行治疗的冠心病心衰患者86例作为研究对象,通过动态随机法进行分组,观察组(43例,美托洛尔联合曲美他嗪治疗)与对照组(43例,美托洛尔治疗),比较治疗前后两组患者的心功能指标、BNP水平以及炎性因子指标,同时对比两组临床治疗总有效率。结果治疗后,观察组LVESD(31.14±2.15)mm、LVEDD(50.42±2.33)mm低于对照组,LVEF(63.44±2.18)%高于对照组,TNF-α(20.45±3.65)ng/L、CRP(3.74±1.12)m/L、BNP(214.46±5.38)pg/mL水平低于对照组,差异有统计学意义(t=17.382、14.476、16.915,16.035、11.949、27.769,P<0.05);观察组临床治疗总有效率93.02%高于对照组74.42%,差异有统计学意义(χ^(2)=5.460,P<0.05)。结论美托洛尔联合曲美他嗪对冠心病心衰疗效确切,可有效改善患者心功能,因此该种疗法可用于临床推广。
Objective To investigate the effect of combined administration of metoprolol and trimetazidine in patients with coronary heart disease and heart failure.Methods A total of 86 patients with coronary heart disease and heart failure who were treated in the hospital from April 2019 to April 2020 were selected as the research objects,and they were grouped by dynamic randomization.The observation group(43 cases,metoprolol combined Metazine treatment)and the control group(43 cases,metoprolol treatment)and the comparison of the cardiac function indexes,BNP levels and inflammatory factor indexes of the two groups of patients before and after treatment,and the total effective rate of clinical treatment between the two groups.Results After treatment,LVESD(31.14±2.15)mm and LVEDD(50.42±2.33)mm in the observation group were lower than those in the control group,LVEF was(63.44±2.18)%higher than those in the control group,and TNF-α(20.45±3.65)ng/L,the levels of CRP(3.74±1.12)m/L and BNP(214.46±5.38)pg/mL were lower than those of the control group,and the difference was statistically significant(t=17.382,14.476,16.915,16.035,11.949,27.769,P<0.05);the total effective rate of clinical treatment in the observation group was 93.02%higher than that in the control group 74.42%,and the difference was statistically significant(χ^(2)=5.460,P<0.05).Conclusion Metoprolol combined with trimetazidine has a definite effect on coronary heart disease and heart failure,and can effectively improve the heart function of patients.Therefore,this therapy can be used for clinical promotion.
作者
贾志刚
JIA Zhigang(Department of Internal Medicine,Liangshan Boai Hospital,Liangshan,Shandong Province,272600 China)
出处
《系统医学》
2021年第14期57-59,共3页
Systems Medicine
关键词
冠心病
心力衰竭
美托洛尔
曲美他嗪
心功能
Coronary heart disease
Heart failure
Metoprolol
Trimetazidine
Heart function
